PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Union Korea Pharm officially exited court-led corporate rehabilitation on August 31, 2026, and has begun normalization under Bukwang Pharmaceutical's ownership, even as revenue contraction and operating losses continue.
After entering rehabilitation in September 2025 and receiving court approval of the reorganization plan in May 2026, the company formally exited court receivership on August 31, 2026.
Bukwang Pharmaceutical injected KRW 30 billion to secure a 75.14% stake, becoming the largest shareholder on May 27 and replacing the entire board on July 21.
A debt-to-equity conversion, reverse stock split, and third-party share issuance sharply increased shares outstanding, heavily diluting existing shareholders' stakes.
Operating losses persisted for four consecutive years through 2025, while revenue shrank from KRW 61.3 billion in 2022 to KRW 36.4 billion in 2025.
Net income attributable to owners turned positive in the second quarter of 2026, but the operating loss persisted, meaning the nature of the improvement warrants scrutiny.
Union Korea Pharm is a prescription drug manufacturer based at its Munmak plant in Wonju, Gangwon Province, producing finished dosage forms including tablets, liquid injectables, and cephalosporin powder injectables.
Its main products include antibiotics for infectious disease treatment, musculoskeletal products for arthritis treatment, cardio-cerebrovascular products, and gastrointestinal treatments, alongside contract manufacturing (CMO) services for other pharmaceutical companies.
The company supplies products domestically and to export markets including the Middle East, Southeast Asia, and Latin America. However, the company had reportedly relied heavily on contract sales organizations (CSOs) rather than an in-house sales force.
In October 2024, allegations of roughly KRW 19.4 billion in embezzlement and breach of trust by controlling shareholders surfaced, destabilizing management, and subsequent disclosures over thirteen occasions raised the cumulative alleged amount to KRW 26 billion.
As the funding crunch deepened, the company filed for court-led rehabilitation with the Seoul Bankruptcy Court in September 2025, and following a stalking-horse public auction, Bukwang Pharmaceutical was selected as the final acquirer in January 2026.
Under the reorganization plan, a large portion of rehabilitation claims was converted into equity, existing and newly converted shares underwent a 3-for-1 reverse split, and Bukwang paid in KRW 30 billion through a third-party share issuance to secure a 75.14% stake and become the largest shareholder.
At an extraordinary general meeting in July 2026, all seven existing board members resigned and four new directors from Bukwang and its parent OCI Group—including new CEO Sung Kwang-hyun and new Vice President Kim Sung-soo—were appointed, establishing a new normalization framework.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩10.2B | -₩2.9B | −28.5% |
| 2025Q3 | ₩7.1B | -₩9.9B | −139.0% |
| 2025Q4 | ₩6.5B | -₩2.6B | −40.9% |
| 2026Q1 | ₩5.9B | -₩1.6B | −26.5% |
| 2026Q2 | ₩5.9B | -₩1.3B | −21.1% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩61.3B | ₩1.3B | -₩900M | 2.1% | −1.9% | 131.5% |
| 2023 | ₩63.2B | -₩5.2B | -₩18.2B | −8.3% | −59.9% | 211.4% |
| 2024 | ₩51.3B | -₩13.5B | -₩20.9B | −26.2% | −253.0% | 808.0% |
| 2025 | ₩36.4B | -₩17.2B | -₩30.8B | −47.4% | — | −300.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Confirmed annual results show a structural downturn. In 2022, revenue was KRW 61.29 billion with operating profit of KRW 1.27 billion (operating margin 2.1%), but in 2023, despite a modest revenue increase to KRW 63.17 billion, the company swung to an operating loss of KRW 5.23 billion (margin -8.3%).
In 2024, revenue fell to KRW 51.28 billion and the operating loss widened to KRW 13.45 billion (margin -26.2%), and in 2025 revenue declined further to KRW 36.38 billion while the operating loss expanded to KRW 17.23 billion (margin -47.4%).
Net losses attributable to owners also widened each year, from KRW 0.93 billion in 2022 to KRW 18.16 billion in 2023, KRW 20.87 billion in 2024, and KRW 30.82 billion in 2025.
Owners' equity at end-2025 stood at negative KRW 22.9 billion, marking full capital impairment, a sharp deterioration from positive equity of KRW 48.6 billion four years earlier.
On a quarterly basis, the operating loss widened sharply to KRW 9.91 billion in the third quarter of 2025, with net loss reaching KRW 11.02 billion that quarter and KRW 13.13 billion in the fourth quarter, marking the deepest loss period.
Losses then narrowed, with first-quarter 2026 revenue of KRW 5.90 billion, an operating loss of KRW 1.57 billion, and a net loss of KRW 2.29 billion, followed by second-quarter 2026 revenue of KRW 5.94 billion and an operating loss of KRW 1.25 billion, while net income attributable to owners turned positive at KRW 2.14 billion.
However, the fact that net income turned positive while the operating loss persisted suggests the result likely reflects one-off gains tied to debt restructuring and debt-to-equity conversion under the rehabilitation plan, making it premature to call this a full operational recovery.
It is also worth noting that the combined net loss attributable to owners over the most recent four quarters (Q3 2025 through Q2 2026) still totaled KRW 24.30 billion, indicating the cumulative deficit remains sizable.
Small and mid-sized domestic prescription drug and generic manufacturers are exposed to ongoing government drug price cuts and fluctuations in the exchange rate for imported active pharmaceutical ingredients, both of which are key variables for defending operating margins.
Indeed, generic drug price cuts are scheduled for the second half of 2026, putting companies with alternative revenue sources such as improved new drugs or CMO business in a relatively favorable position.
Competitors with business structures similar to Union Korea Pharm's have pursued strategies to diversify policy risk by expanding CMO and export exposure and strengthening improved-drug portfolios.
The contract manufacturing (CMO) segment is an area where Korean pharmaceutical companies' capacity constraints repeatedly come into focus; Bukwang Pharmaceutical's Ansan plant has reportedly operated above 100% utilization continuously since 2023, underscoring the need for additional production capacity.
Against this backdrop, the acquisition of Union Korea Pharm can be interpreted as an opportunity for Bukwang to expand capacity, including liquid injectables, and for Union Korea Pharm to secure a stable source of demand.
However, Union Korea Pharm's plant utilization rate stood at only about 20% at the end of 2025, notably below industry norms, and is cited as the top priority for normalization.
Across the industry, reliance on contract sales organizations (CSOs) is under renewed scrutiny, with Union Korea Pharm cited as a case where excessive agency fees eroded profitability.
Bukwang Pharmaceutical has set a target of achieving profitability for Union Korea Pharm within the year through the acquisition, prioritizing production system realignment and normalization of plant utilization.
Specifically, the companies are building a division of labor in which some over-the-counter (OTC) products previously made at Bukwang's Ansan plant are transferred to Union Korea Pharm's plant to be produced under a contract manufacturing (CMO) arrangement, while Bukwang concentrates on prescription drugs and core essential medicines.
A combination digestive tablet was first shipped from Union Korea Pharm's plant in June 2026, and thyroid and endocrine-related over-the-counter tablets are scheduled to begin shipping from Union Korea Pharm's production starting in September.
The company has set a target of raising utilization of its dedicated cephalosporin antibiotic production line from near 100% currently to around 120%, alongside plans for workforce reinforcement and expanded external CMO orders.
In addition, the previously excessive contract sales organization (CSO) fee structure is under review, with Bukwang reportedly in discussions with CSOs on fee adjustments.
With the formal conclusion of court rehabilitation on August 31, 2026, much of the balance-sheet uncertainty has been resolved, and the company stated that its residual debt ratio has fallen to roughly 15% once ordinary operating liabilities such as trade payables and return-related provisions are excluded.
Nonetheless, translating these normalization measures into an actual revenue recovery and operating profit improvement will likely take time, and the pace of progress will need to be confirmed through upcoming quarterly disclosures.
Persistent operating and net losses in recent years have left the company with negative earnings per share, placing it in a range where a conventional price-to-earnings ratio is difficult to compute meaningfully.
By contrast, the price-to-book ratio is set against a net asset value recalculated after the debt-to-equity conversion, reverse split, and share issuance under the rehabilitation plan, and its level below book value suggests the market remains cautious about the durability of the balance-sheet improvement.
The company currently pays no dividend, so dividend-based valuation metrics offer little support.
Looking at the multi-year earnings trend, operating profit moved from a surplus in 2022 to three consecutive years of losses from 2023 through 2025, with net losses widening each year, before net income attributable to owners turned positive in the first half of 2026—a directional shift worth noting.
However, because this swing to profitability may have been influenced by one-off factors related to debt restructuring, whether an underlying operational improvement has actually taken hold will require confirmation over the next several quarters of results.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The company stated that following the formal conclusion of rehabilitation on August 31, 2026, full capital impairment was resolved and the residual debt ratio fell to roughly 15%. Most legacy burdens including unpaid trade payables, borrowings, and bonds with warrants have been settled.
The going-concern-related disclaimer of opinion issued for two consecutive years now has room to be resolved as the balance sheet improves.
Bukwang Pharmaceutical became the largest shareholder with a 75.14% stake and replaced the entire management team to strengthen normalization execution. Contract manufacturing cooperation has already begun, transferring some OTC products from the overloaded Ansan plant to Union Korea Pharm's facility.
The company has also set a target of raising its cephalosporin line utilization to 120% and plans to expand external CMO orders.
Net income attributable to owners turned positive at KRW 2.14 billion in the second quarter of 2026, breaking a streak of net losses over the prior five quarters. The operating loss also narrowed steadily from KRW 9.91 billion in the third quarter of 2025 to KRW 1.25 billion in the second quarter of 2026.
Management's stated target of achieving profitability within the year, alongside the conclusion of rehabilitation, reflects a degree of confidence.
Revenue fell sharply from KRW 61.29 billion in 2022 to KRW 36.38 billion in 2025, and remained around KRW 5.90-5.94 billion per quarter in the first and second quarters of 2026. Plant utilization stood at only about 20% at the end of 2025, suggesting normalization may require considerable time and investment.
The pace of recovery in sales networks and customer relationships weakened during the management dispute period is also a variable to watch.
The operating loss widened for three consecutive years from 2023 through 2025, with the operating margin deteriorating to -47.4% in 2025. The operating loss continued through the first half of 2026 as well, so the possibility that the second-quarter net income turnaround relied on one-off factors cannot be ruled out.
A genuine profitability recovery can only be confirmed once revenue recovery and cost structure improvement occur together.
Shares outstanding increased sharply due to the large-scale debt-to-equity conversion and third-party share issuance under the rehabilitation plan, substantially diluting existing shareholders' influence.
As the ownership change to Bukwang is still recent, how much of the new management's pharmaceutical operating experience and integration synergy will actually materialize remains to be verified.
The final outcome of legal proceedings related to the listing eligibility review stemming from the past embezzlement and breach-of-trust case also remains to be seen.
After allegations of roughly KRW 19.4 billion in embezzlement and breach of trust by controlling shareholders were first disclosed in October 2024, thirteen subsequent disclosures raised the cumulative alleged amount to KRW 26 billion.
This episode led to disclaimer-of-opinion audit results for two consecutive years, designation for listing eligibility review, and an eventual delisting resolution.
Whether internal controls have been genuinely rebuilt under the new management will need continuous verification through future audit reports and disclosures.
The KOSDAQ Market Committee resolved to delist the company on April 3, 2026, but a court injunction filed by the company suspended follow-on procedures such as liquidation trading.
While financial uncertainty has eased following the conclusion of rehabilitation, the final outcome of the legal dispute over the legality of the delisting decision has not yet been determined, and the outcome could affect continued trading eligibility.
Although management has set a target of achieving profitability within the year, this goal requires the simultaneous success of multiple execution tasks including expanding plant utilization, transferring CMO production, and renegotiating CSO fees.
External variables such as raw material exchange rates, drug pricing policy, and competitor responses could also affect the pace of earnings improvement. As the normalization process is still in its early stages, whether and when the target is achieved may remain fluid.
The third-quarter 2026 report will show the pace of revenue recovery and whether the operating loss narrows further, as well as whether the second-quarter net income turnaround was a one-off or is continuing.
It is worth monitoring through disclosures and press reports whether Bukwang's products transferred for production at Union Korea Pharm's plant (such as calchewable tablets) ship as planned and whether external CMO orders actually increase.
The progress and any final ruling in the court proceedings over the injunction against the delisting decision should be confirmed.
The FY2026 audit report should be checked to see whether the audit opinion shifts to 'unqualified' and whether the company's targeted full-year profitability is actually achieved.
Union Korea Pharm went through a delisting crisis and court-led rehabilitation triggered by a large-scale embezzlement and breach-of-trust case involving its former controlling shareholders, formally exiting court receivership under Bukwang Pharmaceutical's ownership on August 31, 2026.
In the process, a large debt-to-equity conversion, reverse stock split, and share issuance resolved full capital impairment on the balance sheet, but heavily diluted existing shareholders' influence.
Annual results moved from a profit in 2022 to three consecutive years of widening operating losses from 2023 through 2025, with revenue roughly halving over the same period.
Net income attributable to owners turned positive in the second quarter of 2026, but the operating loss continued, so whether this represents a structural improvement or a temporary effect of debt restructuring will need to be confirmed through future quarterly results.
Bukwang has set a target of achieving profitability within the year through plant utilization normalization, CMO production transfers, and CSO fee renegotiation, and the execution and pace of these initiatives are likely to be key variables for future earnings and share price expectations.
The final outcome of legal proceedings related to listing eligibility also remains an open matter requiring continued monitoring.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.